Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label DNL310 study in pediatric Hunter syndrome
NL-OMON54074Phase 2Recruiting
- Sponsor
- Denali Therapeutics Inc.
- Start
- Nov 2021
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of tividenofusp alfa in mucopolysaccharidosis type 2 (5 cohorts), sponsored by Denali Therapeutics Inc. Primary endpoints: Incidence and severity of treatment-emergent adverse events, Change from baseline in safety assessments and 2 more. Started Nov 2021; status: recruiting.
02
Drugs
tividenofusp alfa
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on NL-OMON54074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54074.